Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing 100730, China.
Department of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing 100730, China.
Dis Markers. 2022 Mar 4;2022:4487435. doi: 10.1155/2022/4487435. eCollection 2022.
Receptor for advanced glycation end products (RAGE) is implicated in tumor biology. Released high mobility group box protein 1 (HMGB1) ligand binding to RAGE receptor in tumor cells promotes tumor progression. The mechanisms of HMGB1-RAGE signaling in M2 macrophages involved in lymphangiogenesis in laryngeal carcinoma remain poorly understood. Here, we assessed the effect of HMGB1-RAGE signaling on M2 macrophages in lymphangiogenesis.
HMGB1, CD163, and D2-40 in laryngeal squamous cell carcinoma (LSCC, = 123), laryngeal precursor lesions (LPLs, = 102), and vocal polyp (VP, = 55) were analyzed by immunohistochemistry. THP-1 cell-expressed RAGE gene was knocked down and then polarized to M0 macrophages and M2 macrophages. IL-23, TNF-, TGF-, and IL-10 were measured by ELISA; IL-1, IL-12, IL-10, and CCL-13 were evaluated by RT-qPCR, and CD206, CD163, and RAGE were evaluated by western blot to evaluate whether classical M2 macrophages were obtained. Conditioned media from RAGE M0 macrophages and RAGE M2 macrophages incubated in the presence or absence of HMGB1, anti-Toll-like receptor (TLR)2, anti-TLR4 antibodies, and anti-VEGF-C antibodies were collected separately for human dermal lymphatic endothelial cells (HDLEC) for proliferation, migration, lymphangiogenesis assay, and VEGF-C concentration analysis.
HMGB1 and M2 macrophage densities were increased in LSCC ( < 0.01). HMGB1 and M2 macrophage densities were significantly correlated with lymphatic vessel density (LVD) in LSCC ( < 0.01). The HMGB1 overexpression and higher M2 macrophage density were involved in lymph node metastasis ( < 0.01) and poor prognosis ( < 0.05). , conditioned medium from HMGB1-stimulated RAGE M2 macrophages activated lymphangiogenesis by upregulating the VEGF compared to controls ( < 0.05). On the contrary, RAGE knockdown obviously decreased the corresponding effects of HMGB1-preconditioned M2 macrophages upon HDLEC ( < 0.05). HMGB1-TLR pathway does not significantly increase HDLEC proliferation, migration, and lymphangiogenesis on M2 macrophages.
HMGB1 promotes lymphangiogenesis by activation of RAGE on M2 macrophages. Targeting RAGE may provide an effective therapeutic strategy against M2 macrophages in LSCC patients with lymph node metastasis.
晚期糖基化终产物受体(RAGE)参与肿瘤生物学。肿瘤细胞中高迁移率族蛋白 B1(HMGB1)与 RAGE 受体的配体结合促进肿瘤进展。HMGB1-RAGE 信号通路在喉癌中参与 M2 巨噬细胞淋巴管生成的机制仍知之甚少。本研究评估了 HMGB1-RAGE 信号通路对 M2 巨噬细胞淋巴管生成的影响。
采用免疫组织化学法检测 123 例喉鳞状细胞癌(LSCC)、102 例喉前病变(LPL)和 55 例声带息肉(VP)中 HMGB1、CD163 和 D2-40 的表达。用 HMGB1 处理 THP-1 细胞诱导其表达 RAGE 基因,然后将其极化为 M0 巨噬细胞和 M2 巨噬细胞。采用 ELISA 法检测 IL-23、TNF-、TGF-和 IL-10 的水平;采用 RT-qPCR 法检测 IL-1、IL-12、IL-10 和 CCL-13 的水平;采用 Western blot 法检测 CD206、CD163 和 RAGE 的水平,以评估是否获得了经典的 M2 巨噬细胞。分别收集 RAGE M0 巨噬细胞和 RAGE M2 巨噬细胞在有或没有 HMGB1、抗 Toll 样受体(TLR)2、抗 TLR4 抗体和抗 VEGF-C 抗体孵育条件下的条件培养基,用于人真皮淋巴管内皮细胞(HDLEC)增殖、迁移、淋巴管生成实验和 VEGF-C 浓度分析。
LSCC 中 HMGB1 和 M2 巨噬细胞密度增加( < 0.01)。HMGB1 和 M2 巨噬细胞密度与 LSCC 中的淋巴管密度(LVD)呈显著正相关( < 0.01)。HMGB1 过表达和更高的 M2 巨噬细胞密度与淋巴结转移( < 0.01)和预后不良( < 0.05)有关。与对照组相比,HMGB1 刺激的 RAGE M2 巨噬细胞条件培养基中 VEGF 上调,促进淋巴管生成( < 0.05)。相反,RAGE 敲低明显降低了 HMGB1 预处理的 M2 巨噬细胞对 HDLEC 的相应作用( < 0.05)。HMGB1-TLR 途径在 M2 巨噬细胞上不会显著增加 HDLEC 的增殖、迁移和淋巴管生成。
HMGB1 通过 RAGE 激活 M2 巨噬细胞促进淋巴管生成。靶向 RAGE 可能为伴有淋巴结转移的 LSCC 患者的 M2 巨噬细胞提供一种有效的治疗策略。